Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 565-574 , August 2010

Stem cells in the treatment of inflammatory arthritis

  • Alan Tyndall, MD (Professor and Head of Rheumatology)

      Affiliations

    • Department of Rheumatology, University of Basel, Switzerland
    • ,
  • Jacob M. van Laar, MD, PhD (Professor of Clinical Rheumatology)

      Affiliations

    • Musculoskeletal Research Group, Institute of Cellular Medicine, Framlington Place, 4th Floor Cookson Building, Newcastle upon Tyne, NE2 4HH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 191 222 3449; Fax: +44 191 222 5455.

References 

  1. Alivernini S, Laria A, Gremese E, et al. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Research & Therapy. 2009;11:R163
  2. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Research & Therapy. 2009;11:229
  3. van Bekkum DW. Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Practice & Research. Clinical Haematology. 2004;17:201–222
  4. Flierman R, Witteveen HJ, van der Voort EI, et al. Control of systemic B-cell mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation. Blood. 2005;105:2991–2994
  5. McGonagle D, Rawstron A, Richards S, et al. A phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritis. Arthritis and Rheumatism. 1997;40:1838–1842
  6. Verburg RJ, Flierman R, Sont JK, et al. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Annals of the Rheumatic Diseases. 2005;64:1397–1405
  7. Bingham SJ, Snowden J, McGonagle D, et al. Autologous stem cell transplantation for rheumatoid arthritis–interim report of 6 patients. The Journal of Rheumatology. Supplement. 2001;64:21–24
  8. Teng YK, Verburg RJ, Sont JK, et al. Long-term follow-up of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. Arthritis and Rheumatism. 2005;52:2272–2276
  9. Verburg RJ, Sont JK, van Laar JM. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation. Arthritis and Rheumatism. 2005;52:421–424
  10. Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. The Journal of Rheumatology. 2004;31:482–488
  11. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Haematologica. 2009 Sep 22;[Epub ahead of print]
  12. Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:2301–2309
  13. Moore J, Ma D, Will R, et al. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2004;34:241–247
  14. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. The Journal of Rheumatology. 1998;25:1991–1994
  15. Brinkman DM, de Kleer IM, ten Cate R, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis and Rheumatism. 2007;56:2410–2421
  16. Abinun M, Flood TJ, Cant AJ, et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000–2007). Molecular Immunology. 2009;47:46–51
  17. Takken T, van den Beuken C, Wulffraat NM, et al. Exercise tolerance in children with juvenile idiopathic arthritis after autologous SCT. Bone Marrow Transplantation. 2008;42:351–356
  18. de Kleer I, Vastert B, Klein M, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T-cells and restoring the CD4+CD25+ immune regulatory network. Blood. 2005;
  19. Roord ST, de Jager W, Boon L, et al. Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells. Blood. 2008;111:5233–5241
  20. Teng YK, Verburg RJ, Verpoort KN, et al. Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study. Arthritis Research & Therapy. 2007;9:R106
  21. Brinkman DM, ten Cate R, Vossen JM, et al. Decrease in synovial cellularity and cytokine expression after autologous stem cell transplantation in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism. 2002;46:1121–1123
  22. Bingham S, Veale D, Fearon U, et al. High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis and Rheumatism. 2002;46:837–839
  23. Ponchel F, Verburg RJ, Bingham SJ, et al. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Research & Therapy. 2005;7:R80–R92
  24. Ponchel F, Morgan AW, Bingham SJ, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood. 2002;100:4550–4556
  25. Horwitz E, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7:393–395
  26. Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplantation. 2009;43:821–828
  27. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews. Immunology. 2008;8:726–736
  28. Djouad F, Fritz V, Apparailly F, et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis and Rheumatism. 2005;52:1595–1603
  29. Augello A, Tasso R, Negrini SM, et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis and Rheumatism. 2007;56:1175–1186
  30. Choi JJ, Yoo SA, Park SJ, et al. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clinical and Experimental Immunology. 2008;153:269–276
  31. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scandinavian Journal of Immunology. 2003;57:11–20
  32. Bocelli-Tyndall C, Bracci L, Spagnoli G, et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford). 2007;46:403–408
  33. Gonzalez-Rey E, Gonzalez MA, Varela N, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2009;
  34. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–1586
  35. Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Diseases of the Colon and Rectum. 2005;48:1416–1423
  36. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iranian Journal of Immunology. 2007;4:50–57
  37. Riordan NH, Ichim TE, Min WP, et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. Journal of Translational Medicine. 2009;7:29
  38. Liang J, Zhang H, Hua B, et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Multiple Sclerosis. 2009;15:644–646
  39. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Archives of Iranian Medicine. 2007;10:459–466
  40. Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27:1421–1432
  41. Williams BA, Keating A. Cell therapy for age-related disorders: myocardial infarction and stroke–a mini-review. Gerontology. 2008;54:300–311
  42. Larghero J, Farge D, Braccini A, et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Annals of the Rheumatic Diseases. 2008;67:443–449
  43. Marinova-Mutafchieva L, Williams RO, Funa K, et al. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis and Rheumatism. 2002;46:507–513
  44. Tomita T, Takeuchi E, Toyosaki-Maeda T, et al. Establishment of nurse-like stromal cells from bone marrow of patients with rheumatoid arthritis: indication of characteristic bone marrow microenvironment in patients with rheumatoid arthritis. Rheumatology (Oxford). 1999;38:854–863
  45. Jones E, Churchman SM, English A, et al. Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level. Annals of the Rheumatic Diseases. 2009;
  46. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441

PII: S1521-6942(10)00009-4

doi: 10.1016/j.berh.2010.01.008

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 565-574 , August 2010

Article Tools

* Image Usage & Resolution